DEFA14A: Avadel Receives Unsolicited $23/Share Acquisition Bid from Lundbeck

Avadel Pharmaceuticals plc announced it received an unsolicited acquisition proposal from H. Lundbeck A/S for up to $23.00 per share, potentially challenging its existing agreement with Alkermes.

Summary

• Avadel Pharmaceuticals plc received an unsolicited proposal from H. Lundbeck A/S on November 13, 2025, to acquire the company for up to $23.00 per ordinary share.
• The proposal consists of $21.00 per ordinary share in cash at closing.
• It also includes a non-transferable contingent value right (CVR) for potential additional cash payments of $1.00 per share if LUMRYZ and valiloxybate collectively reach $450 million in annual U.S. net sales by December 31, 2027.
• A second CVR for $1.00 per share is contingent upon LUMRYZ and valiloxybate collectively reaching $700 million in annual U.S. net sales by December 31, 2030.
• Avadel's Board of Directors, after consulting advisors, determined Lundbeck's proposal is "reasonably expected to result in a Company Superior Proposal" as defined in its existing transaction agreement with Alkermes.
• Avadel expects to provide information to and conduct discussions and negotiations with Lundbeck regarding its proposal.
• The Board has not yet determined that Lundbeck's proposal is a "Company Superior Proposal" and has not changed its recommendation in support of the acquisition by Alkermes.

Sentiment

Score: 7

Explanation: The receipt of an unsolicited, potentially superior acquisition offer is generally positive for shareholders, indicating increased value. However, the uncertainty surrounding the Board's final determination and the contingent nature of part of the offer temper the sentiment.

Positives

• Receipt of an unsolicited acquisition proposal from H. Lundbeck A/S for up to $23.00 per share, potentially offering a higher valuation than the existing Alkermes agreement.
• The Board's determination that Lundbeck's proposal is "reasonably expected to result in a Company Superior Proposal" indicates a credible and potentially more favorable offer for shareholders.
• The CVRs offer additional upside potential based on the future sales performance of LUMRYZ and valiloxybate, aligning shareholder interests with product success.

Negatives

• Uncertainty remains as the Board has not yet determined Lundbeck's proposal is a Company Superior Proposal and has not changed its recommendation for the Alkermes acquisition.
• There is no assurance that discussions with Lundbeck will result in a definitive agreement or a determination of a Superior Proposal.
• The CVRs introduce contingency and future performance risk, as the additional $2.00 per share is not guaranteed.

Risks

• The ability of the parties to consummate the acquisition in a timely manner or at all.
• Satisfaction (or waiver) of conditions to the consummation of the acquisition, including shareholder and regulatory approvals.
• The potential impact of the unsolicited proposal from Lundbeck or the possibility that more competing offers may be made.
• Potential delays in consummating the acquisition.
• The ability of Avadel to timely and successfully achieve the anticipated benefits of the acquisition.
• The occurrence of any event, change or other circumstance or condition that could give rise to the termination of the transaction agreement.
• The effect of the announcement or pendency of the acquisition on Avadel's business relationships, operating results, and business generally.
• Costs related to the acquisition.
• The outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the transaction agreement or the acquisition.
• Actual outcomes and results may differ materially from forward-looking statements due to uncertainties and changes in circumstances.
• The unsolicited proposal from Lundbeck may not result in a definitive agreement for an alternative business combination transaction.

Future Outlook

Avadel expects to engage in discussions and negotiations with Lundbeck regarding its unsolicited acquisition proposal. The Board will assess if this proposal constitutes a "Company Superior Proposal" compared to the existing agreement with Alkermes. There is no assurance that these discussions will lead to a definitive agreement or a change in the Board's current recommendation for the Alkermes acquisition. Business operations are expected to continue as usual during this period.

Management Comments

• "I am writing to let you know about a recent development regarding our Company."
• "Today we issued a press release confirming that on November 13, 2025, Avadel Pharmaceuticals plc received an unsolicited proposal from H. Lundbeck A/S (Lundbeck) to acquire the Company for up to $23.00 per share."
• "After consultation with our financial and legal advisors, the Avadel Board reached such a determination with respect to Lundbeck’s proposal. Accordingly, we expect to provide information to and conduct discussions and negotiations with Lundbeck regarding its proposal."
• "It is important to note that Avadel’s Board has not determined that Lundbeck’s proposal in fact constitutes a Company Superior Proposal and at this time, has not changed its recommendation in support of the acquisition by Alkermes."
• "Further, there can be no assurance that our discussions with Lundbeck will result in a determination by the Board that the Lundbeck proposal is a Company Superior Proposal."
• "While these discussions are ongoing, it continues to be business as usual for all of us at Avadel."
• "We expect this announcement will lead to inquiries from external parties and it is important for us to speak with one voice. Consistent with company policy, please do not respond to any inquiries received from members of the media, investment community or other interested parties, and instead forward them to investors@avadel.com."

Industry Context

This development highlights ongoing consolidation and strategic interest within the pharmaceutical sector, particularly for companies with promising drug assets like LUMRYZ and valiloxybate. The unsolicited bid from Lundbeck, a major global pharmaceutical company, for Avadel, which already has an agreement with Alkermes, suggests a competitive landscape for acquiring innovative drug pipelines and market share. The CVR structure indicates the acquiring parties see significant potential in Avadel's products but also want to share the risk and reward of their future commercial success.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the offer against global benchmarks.
• The offer structure, including a cash component and contingent value rights (CVRs), is a common mechanism in pharmaceutical M&A to bridge valuation gaps and share future product performance risks and rewards, especially for assets with significant but unproven commercial potential like LUMRYZ and valiloxybate.
• Without the specific terms of the Alkermes offer, a direct comparison of the Lundbeck proposal's value against the existing agreement or other recent industry acquisitions is not possible from this document alone.

Corporate Governance

Legal Proceedings

• The outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the transaction agreement or the acquisition.

Stakeholder Impact

• Shareholders: Potential for a higher acquisition price and increased shareholder value if the Lundbeck proposal is deemed superior and proceeds. Uncertainty regarding the final outcome of the acquisition process.
• Employees: Instructed to continue with business as usual, but the ongoing acquisition discussions may create uncertainty regarding future employment and company direction.
• Customers/Patients: Continued service to patients is emphasized by management.
• Alkermes: The existing transaction agreement with Alkermes is now challenged by a competing, potentially superior offer, which could lead to its termination or renegotiation.
• Lundbeck: Engaged in discussions to potentially acquire Avadel, indicating strategic interest in Avadel's assets.

Next Steps

• Avadel to provide information to and conduct discussions and negotiations with Lundbeck regarding its proposal.
• Avadel's Board of Directors to determine if Lundbeck's proposal constitutes a "Company Superior Proposal."
• Further public comments from Avadel are not expected until the Board completes discussions and/or negotiations with Lundbeck.
• Shareholders will need to read the definitive proxy statement (including the scheme document) and other relevant documents filed with the SEC before making any voting decision on the acquisition.

Key Dates

Recommendation

The filing indicates an unsolicited acquisition proposal from Lundbeck that the Avadel Board considers "reasonably expected to result in a Company Superior Proposal" compared to the existing Alkermes agreement. This creates a competitive situation that could lead to a higher offer for Avadel shareholders. However, the Board has not yet formally declared Lundbeck's offer as superior, and discussions are ongoing with no guarantee of a definitive agreement. An investor should hold their position to await further clarity on the outcome of these negotiations and the Board's final recommendation, as the situation is fluid and could result in a more favorable outcome or a return to the original Alkermes deal.

Keywords

Avadel Pharmaceuticals, Lundbeck, Alkermes, Acquisition Proposal, Merger, Takeover, Contingent Value Right, CVR, LUMRYZ, valiloxybate, Pharmaceuticals, SEC Filing, DEFA14A